Firecrawl Alexandria

ClinicalTrials.gov

Name: ClinicalTrials.gov
Creator: ClinicalTrials.gov

ClinicalTrials.gov study registry via the public v2 REST API: search studies by condition, intervention, sponsor, location, status or Essie expression with page-token pagination; fetch one study record by NCT number; batch-resolve the raw ACTUAL/ESTIMATED start, primary-completion and completion dates for known NCT numbers; autocomplete conditions, interventions, sponsors and facilities; and read registry-wide field value statistics.

12 Firecrawl tools use ClinicalTrials.gov

Try in Agent

Find the first 10 recruiting breast cancer studies involving pembrolizumab and show their NCT IDs, sponsors and start dates with ACTUAL or ESTIMATED labels.

Try ClinicalTrials.gov now.

Choose an example or ask your own question.

What do you want to do with ClinicalTrials.gov?

ClinicalTrials.gov

TRY ASKING

Codefollows the fields above

const result = await firecrawl.scrape({
  alexandria: {
    provider: "clinicaltrials-gov",
    capability: "clinical-trials/study",
    options: {
      fields: [
        "IdentificationModule",
        "StatusModule",
        "HasResults",
      ],
      nct_id: "NCT05159778",
    },
  },
});

2Response example

This is a sample shape. Press Run to see live data from ClinicalTrials.gov.

{
  "api_url": "https://clinicaltrials.gov/api/v2/studies/NCT05159778?fields=IdentificationModule,StatusModule,HasResults,NCTId",
  "brief_title": "Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)",
  "completion_date": {
    "date": "2023-04-12",
    "type": "ACTUAL"
  },
  "has_results": false,
  "nct_id": "NCT05159778",
  "observed_at_ms": 1790705145940,
  "overall_status": "COMPLETED",
  "primary_completion_date": {
    "date": "2023-03-22",
    "type": "ACTUAL"
  },
  "record": {
    "hasResults": false,
    "protocolSection": {
      "identificationModule": {
        "briefTitle": "Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)",
        "nctId": "NCT05159778",
        "officialTitle": "A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy",
        "orgStudyIdInfo": {
          "id": "PGG-BCA2121 / MK-3475-C99"
        },
        "organization": {
          "class": "INDUSTRY",
          "fullName": "HiberCell, Inc."
        }
      },
      "statusModule": {
        "completionDateStruct": {
          "date": "2023-04-12",
          "type": "ACTUAL"
        },
        "expandedAccessInfo": {
          "hasExpandedAccess": false
        },
        "lastUpdatePostDateStruct": {
          "date": "2023-06-22",
          "type": "ACTUAL"
        },
        "lastUpdateSubmitDate": "2023-06-19",
        "overallStatus": "COMPLETED",
        "primaryCompletionDateStruct": {
          "date": "2023-03-22",
          "type": "ACTUAL"
        },
        "startDateStruct": {
          "date": "2021-11-09",
          "type": "ACTUAL"
        },
        "statusVerifiedDate": "2022-07",
        "studyFirstPostDateStruct": {
          "date": "2021-12-16",
          "type": "ACTUAL"
        },
        "studyFirstSubmitDate": "2021-11-10",
        "studyFirstSubmitQcDate": "2021-12-02"
      }
    }
  },
  "source_url": "https://clinicaltrials.gov/study/NCT05159778",
  "start_date": {
    "date": "2021-11-09",
    "type": "ACTUAL"
  }
}